GSK:LON
GSK plc
GBX 1,759.00
arrow_downward
-1.15%(-20.50) 1D
10-р сарын 5, 16:36:51 (GMT+1) · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
GBX 1,786.50
High
GBX 1,790.00
Low
GBX 1,755.00
Mkt. cap
94.05 тэрбум
Avg. vol.
5.45 сая
Volume
3.78 сая
Dividend
3.87%
Quarterly dividend
GBX 17.00
Ex-dividend date
2026 оны 8-р сарын 13
P/E ratio
14.91
52-wk high
GBX 2,282.00
52-wk low
GBX 1,592.00
EPS
GBX 1.18
Shares outstanding
4.05 тэрбум
No. of employees
67 мян
Open
GBX 1,786.50
High
GBX 1,790.00
Low
GBX 1,755.00
Mkt. cap
94.05 тэрбум
Avg. vol.
5.45 сая
Volume
3.78 сая
Dividend
3.87%
Quarterly dividend
GBX 17.00
Ex-dividend date
2026 оны 8-р сарын 13
P/E ratio
14.91
52-wk high
GBX 2,282.00
52-wk low
GBX 1,592.00
EPS
GBX 1.18
Shares outstanding
4.05 тэрбум
No. of employees
67 мян
News stories
From web sources and news partners
Bioscience Association Manitoba
·
6 цагийн өмнө
ViiV HEALTHCARE MAKES NEW £9.75 MILLION INVESTMENT TO ACCELERATE HIV RESPONSE FOR PAEDIATRIC AND ADOLESCENT POPULATION
Traders Union
·
20 цагийн өмнө
Why is GSK stock flat today? Resistance levels in focus
AD HOC NEWS
·
4 сарын өмнө
GSK stock after-hours at EUR 20.74: minus 0.43 percent versus prior close
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8 мян
Founded2000 оны 12-р сарын 27
Headquarters-
SectorPharmaceutical industry
Websitegsk.com